Biocartis Group N.V.
BIOGFOTCHealthcare
$0.66
$-3.84(-85.33%)
Market Cap$65406204
P/E Ratio—
52W High$0.66
52W Low$0.66
Biocartis Group N.V. (BIOGF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOGF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2023Report Date: Jun 30, 2023EPS Actual
-$0.34
Revenue
$0.00B
Fiscal Period
Q2 FY2023
FY ends December
Report Date
Jun 30, 2023
After Market Close
BIOGF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | Jun 13, 2024 | — | — | — | — | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.34 | — | $0.00B | — | — |
| — Q1 FY2023 | Feb 23, 2023 | — | -$0.58 | — | $0.00B | — | — |
| — Q4 FY2022 | Oct 20, 2022 | — | -$0.46 | — | $0.03B | — | — |
| — Q2 FY2022 | Apr 19, 2022 | — | -$0.62 | — | $0.02B | — | — |
| — Q4 FY2021 | Nov 10, 2021 | — | -$0.62 | — | $0.02B | — | — |
| — Q2 FY2021 | May 14, 2021 | — | -$0.56 | — | $0.02B | — | — |
| — Q3 FY2020 | Sep 3, 2020 | — | -$0.56 | — | $0.02B | — | — |
Q2 FY2024
Jun 13, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.34
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Feb 23, 2023
EPS Actual
-$0.58
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Oct 20, 2022
EPS Actual
-$0.46
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q2 FY2022
Apr 19, 2022
EPS Actual
-$0.62
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q4 FY2021
Nov 10, 2021
EPS Actual
-$0.62
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q2 FY2021
May 14, 2021
EPS Actual
-$0.56
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q3 FY2020
Sep 3, 2020
EPS Actual
-$0.56
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2023 | Jun 30, 2023 | — | $0.66 | — | — |
| — Q1 FY2023 | Feb 23, 2023 | — | $0.66 | $0.66 | +0.00% |
| — Q4 FY2022 | Oct 20, 2022 | — | $4.50 | $4.50 | +0.00% |
| — Q2 FY2022 | Apr 19, 2022 | — | $4.50 | $4.50 | +0.00% |
| — Q4 FY2021 | Nov 10, 2021 | — | $4.50 | $4.50 | +0.00% |
| — Q2 FY2021 | May 14, 2021 | — | No price data | $4.50 | — |
| — Q3 FY2020 | Sep 3, 2020 | — | No price data | $4.50 | — |
| — Q1 FY2020 | Mar 5, 2020 | — | No price data | $4.50 | — |
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.66
Price After
—
Q1 FY2023+0.00%
Report Date
Feb 23, 2023
EPS Beat/Miss
—
Price Before
$0.66
Price After
$0.66
Q4 FY2022+0.00%
Report Date
Oct 20, 2022
EPS Beat/Miss
—
Price Before
$4.50
Price After
$4.50
Q2 FY2022+0.00%
Report Date
Apr 19, 2022
EPS Beat/Miss
—
Price Before
$4.50
Price After
$4.50
Q4 FY2021+0.00%
Report Date
Nov 10, 2021
EPS Beat/Miss
—
Price Before
$4.50
Price After
$4.50
Q2 FY2021—
Report Date
May 14, 2021
EPS Beat/Miss
—
Price Before
—
Price After
$4.50
Q3 FY2020—
Report Date
Sep 3, 2020
EPS Beat/Miss
—
Price Before
—
Price After
$4.50
Q1 FY2020—
Report Date
Mar 5, 2020
EPS Beat/Miss
—
Price Before
—
Price After
$4.50
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOGF ends December
Biocartis Group N.V. (BIOGF) most recently reported earnings on June 30, 2023 for Q2 FY2023, posting EPS of $-0.34 (in line with the analyst consensus of —). The next BIOGF earnings date is expected around September 1, 2026.
Each quarter, investors track BIOGF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOGF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOGF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOGF earnings · 4 questionsBiocartis Group N.V.'s next earnings report is expected around September 1, 2026. BIOGF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOGF historically reports after market close (AMC).
BIOGF earnings datewhen is BIOGF earningsBIOGF next earnings datewhen does BIOGF report earningsBIOGF earnings calendar
▸ Source: FMP · Biocartis Group N.V. SEC filings · US GAAP · Biocartis Group N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026